H.R. 1561 · 119th Congress · Health
ALERT Communities Act
Creates alert system for communities to respond to health emergencies. AI-read
- IntroducedFeb 25, 2025 Done
- CommitteeReferred to Energy and Commerce Current stage
- House floorNot yet Not reached yet
- Senate floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill establishes programs and requirements to advance the development and usage of test strips that detect the presence of certain hazardous drugs (e.g., fentanyl, xylazine).
Currently, the Substance Abuse and Mental Health Services Administration provides grants to government entities to train and provide authorized equipment to first responders and other relevant personnel for emergency treatment of opioid overdoses. The bill expands these grants to include rapid response test strips for detecting the presence of fentanyl, xylazine, and other synthetic opioids or emerging substances in people or within other drugs.
Additionally, the bill requires the Department of Health and Human Services (HHS) to publish guidance and standards for test strip manufacturers to support the development, evaluation, and authorization of test strips.
Also, HHS must conduct a study and report to Congress on how the availability and usage of test strips and similar equipment impacts the frequency of overdoses and participation in substance use disorder treatment.
Congressional Research Service · summary of “Introduced in House” version · Feb 25, 2025
Who lobbies on it
2 organizations, more than 77% of House bills · 3 filings · Q1 2025–Q3 2026One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
American Society of Health-System Pharmacists
2 of 7 quarters
“Issues related to vaccine access and evidence-based resources for patients and pharmacists (generally, no specific legislation). Tylers Law (H.R. 2004), the ALERT Communities Act (H.R. 1561), and the HERO Act (H.R. 7994), issues related to access to fentanyl test strips and medications for opioid use disorder (MOUD).…”
$750K lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
American Medical Association
1 of 7 quarters
“H.R.1266 - Combating Illicit Xylazine Act, all provisions H.R.1561 - ALERT Communities Act, all provisions H.R.2004 - Tylers Law, all provisions H.R.7970 - STOP Nitazenes Act, all provisions H.R.7994 - HERO Act, all provisions Comment Letter: [2026-11602] HHS Request for Comment on Chronic Disease of Addiction Chronic…”
$17.6M lobbying spend in 2026 to date, all issuesQ2 2026 filing
Organizations that named H.R. 1561 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
8 actions · newest first- Jul 21, 2026Ordered to be Reported by the Yeas and Nays: 48 - 0.
- Jul 21, 2026Committee Consideration and Mark-up Session Held
- Jul 20, 2026Committee Consideration and Mark-up Session Held
- Jun 25, 2026Forwarded by Subcommittee to Full Committee by Voice Vote.
Show all 8 actionsShow fewer
- Jun 25, 2026Subcommittee Consideration and Mark-up Session Held
- Feb 25, 2025Referred to the Subcommittee on Health.
- Feb 25, 2025Referred to the House Committee on Energy and Commerce.
- Feb 25, 2025Introduced in House